To hear about similar clinical trials, please enter your email below
Trial Title:
68Ga-FAPI PET/CT for the Detection of Adenoid Cystic Carcinoma(ACC)
NCT ID:
NCT05499936
Condition:
68Ga-FAPI PET/CT
Metastatic Adenoid Cystic Carcinoma
Conditions: Official terms:
Carcinoma
Carcinoma, Adenoid Cystic
Conditions: Keywords:
68Ga-FAPI
PET/CT
Adenoid Cystic Carcinoma
Study type:
Interventional
Study phase:
N/A
Overall status:
Unknown status
Study design:
Allocation:
N/A
Intervention model:
Single Group Assignment
Primary purpose:
Diagnostic
Masking:
None (Open Label)
Intervention:
Intervention type:
Drug
Intervention name:
68Ga-FAPI
Description:
68Ga-FAPI were injected into the patients before the PET/CT scans
Arm group label:
68Ga-FAPI PET/CT
Summary:
This study was used to study the diagnostic value of 68Ga-FAPI, a novel fibroblast
activating inhibitor, in metastatic adenoid cystic carcinoma（ACC）
Detailed description:
68Ga-FAPI is a positron labeled inhibitor of fibroblast activating protein, which has
been widely used in malignant tumor imaging in recent years. Adenoid cystic carcinoma
(ACC) is a rare epithelial malignant tumor, which usually originates from salivary
glands. Its typical characteristics are long clinical course and high rate of distant
metastasis. The purpose of this study was to investigate the clinical value of 68Ga Fapi
pet/ct in metastatic adenoid cystic carcinoma.
Criteria for eligibility:
Criteria:
Inclusion Criteria:
- patients with ACC suspected metastatic tumor,and being able to provide basic
information and sign the written informed consent form
Exclusion Criteria:
- claustrophobia, pregnancy, breastfeeding, kidney or liver failure, inability to
fulfill the study
Gender:
All
Minimum age:
18 Years
Maximum age:
80 Years
Healthy volunteers:
No
Locations:
Facility:
Name:
Peking Union Medical College Hospital, Chinese Academy of Medical Science and Peking Union Medical College
Address:
City:
Beijing
Country:
China
Status:
Recruiting
Contact:
Last name:
Rongxi Wang
Contact backup:
Phone:
+8619800370331
Start date:
October 1, 2021
Completion date:
December 31, 2022
Lead sponsor:
Agency:
Peking Union Medical College Hospital
Agency class:
Other
Source:
Peking Union Medical College Hospital
Record processing date:
ClinicalTrials.gov processed this data on November 12, 2024
Source: ClinicalTrials.gov page:
https://clinicaltrials.gov/ct2/show/NCT05499936
